1. Home
  2. JELD vs IPHA Comparison

JELD vs IPHA Comparison

Compare JELD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

N/A

Current Price

$1.04

Market Cap

152.7M

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.43

Market Cap

167.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JELD
IPHA
Founded
1960
1999
Country
United States
France
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
167.6M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
JELD
IPHA
Price
$1.04
$1.43
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$1.93
★ $6.67
AVG Volume (30 Days)
★ 1.3M
17.5K
Earning Date
11-03-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,211,181,000.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
$3.72
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$1.17
52 Week High
$3.27
$2.71

Technical Indicators

Market Signals
Indicator
JELD
IPHA
Relative Strength Index (RSI) 31.30 42.83
Support Level $0.93 $1.38
Resistance Level $1.47 $1.59
Average True Range (ATR) 0.14 0.07
MACD -0.02 0.01
Stochastic Oscillator 19.24 39.29

Price Performance

Historical Comparison
JELD
IPHA

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: